At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 1 enrolled
Drug / intervention
AIDSVAX® B/Ebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 7, 2018·Updated Feb 7, 2022
In Brief
A Phase 1 clinical trial evaluating AIDSVAX® B/E for HIV Infections and Systemic Lupus Erythematosus. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX® B/E) in HIV-uninfected adults diagnosed with Systemic Lupus Erythematosus (SLE) who have stable disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Systemic Lupus Erythematosus
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartDec 2018
Primary CompletionJul 2020
TodayJul 2026
First PostedAug 7, 2018
Enrollment StartDec 19, 2018
Primary CompletionJul 17, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.9 years ago
Interventions
AIDSVAX® B/Ebiological
Administered by intramuscular injection